S100A2 and central nervous system cancer: High S100A2 expression is associated with an unfavorable clinical course in brain tumors, such as low-grade glioma and glioblastoma, NSCLC, hepatocellular carcinoma, ovarian cancer, endometrial carcinoma, pancreatic cancer, prostate cancer, colorectal cancer, and cholangiocarcinoma.